BRPI9612992B1 - Combinação, e, formulação farmacêutica - Google Patents

Combinação, e, formulação farmacêutica Download PDF

Info

Publication number
BRPI9612992B1
BRPI9612992B1 BRPI9612992-1A BRPI9612992A BRPI9612992B1 BR PI9612992 B1 BRPI9612992 B1 BR PI9612992B1 BR PI9612992 A BRPI9612992 A BR PI9612992A BR PI9612992 B1 BRPI9612992 B1 BR PI9612992B1
Authority
BR
Brazil
Prior art keywords
zidovudine
combination
hiv
formulation
ftc
Prior art date
Application number
BRPI9612992-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David Walter Barry
Martha Heider St. Clair
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9612992(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of BRPI9612992B1 publication Critical patent/BRPI9612992B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
BRPI9612992-1A 1995-03-30 1996-03-28 Combinação, e, formulação farmacêutica BRPI9612992B1 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GB9506490.3 1995-03-30
GB9506489.5 1995-03-30
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
BRPI9607851A BRPI9607851B8 (pt) 1995-03-30 1996-03-28 combinação e formulação farmacêutica.

Publications (1)

Publication Number Publication Date
BRPI9612992B1 true BRPI9612992B1 (pt) 2020-08-04

Family

ID=26306774

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI9612992-1A BRPI9612992B1 (pt) 1995-03-30 1996-03-28 Combinação, e, formulação farmacêutica
BRPI9607851A BRPI9607851B8 (pt) 1995-03-30 1996-03-28 combinação e formulação farmacêutica.
BRPI9607851-0A BR9607851B1 (pt) 1995-03-30 1996-03-28 combinaÇço e formulaÇço farmacÊutica.

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI9607851A BRPI9607851B8 (pt) 1995-03-30 1996-03-28 combinação e formulação farmacêutica.
BRPI9607851-0A BR9607851B1 (pt) 1995-03-30 1996-03-28 combinaÇço e formulaÇço farmacÊutica.

Country Status (35)

Country Link
US (1) US6417191B1 (enExample)
EP (1) EP0817637B1 (enExample)
JP (1) JP2954357B2 (enExample)
KR (1) KR100542536B1 (enExample)
CN (1) CN1103593C (enExample)
AP (1) AP652A (enExample)
AT (1) ATE220551T1 (enExample)
AU (1) AU715213B2 (enExample)
BR (3) BRPI9612992B1 (enExample)
CA (1) CA2216634C (enExample)
CZ (1) CZ295940B6 (enExample)
DE (3) DE122005000029I2 (enExample)
DK (1) DK0817637T3 (enExample)
EA (1) EA000626B3 (enExample)
EE (1) EE04047B1 (enExample)
ES (1) ES2179193T3 (enExample)
FR (1) FR05C0022I2 (enExample)
GE (1) GEP20022647B (enExample)
HU (1) HU224010B1 (enExample)
IL (1) IL117727A (enExample)
LU (1) LU91171I2 (enExample)
MX (1) MX9707316A (enExample)
MY (1) MY115461A (enExample)
NL (1) NL300195I2 (enExample)
NO (2) NO313787B1 (enExample)
NZ (1) NZ306419A (enExample)
OA (1) OA10616A (enExample)
PL (1) PL187085B1 (enExample)
PT (1) PT817637E (enExample)
RO (1) RO117995B1 (enExample)
SI (1) SI0817637T1 (enExample)
SK (1) SK283825B6 (enExample)
TR (1) TR199701074T1 (enExample)
UA (1) UA60293C2 (enExample)
WO (1) WO1996030025A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU7912398A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
WO2005040816A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
DK2120878T3 (da) * 2007-02-09 2014-11-03 Alphapharm Pty Ltd Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CN115348864A (zh) 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DE69206876T3 (de) 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
HU224010B1 (hu) 2005-04-28
DE69622386T2 (de) 2003-02-13
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
IL117727A0 (en) 1996-07-23
AP652A (en) 1998-06-19
DE69622386D1 (de) 2002-08-22
HK1009401A1 (en) 1999-09-10
KR100542536B1 (ko) 2006-03-23
NO313787B1 (no) 2002-12-02
IL117727A (en) 1999-11-30
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
MX9707316A (es) 1997-11-29
LU91171I2 (fr) 2005-07-04
MY115461A (en) 2003-06-30
ATE220551T1 (de) 2002-08-15
NO2005014I2 (no) 2008-02-11
CN1185110A (zh) 1998-06-17
EA199700203A1 (ru) 1998-02-26
KR19980703420A (ko) 1998-11-05
AU715213B2 (en) 2000-01-20
JP2954357B2 (ja) 1999-09-27
US6417191B1 (en) 2002-07-09
PL187085B1 (pl) 2004-05-31
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
LU91171I9 (enExample) 2018-12-28
AU5497296A (en) 1996-10-16
DK0817637T3 (da) 2002-11-11
CZ309097A3 (cs) 1998-05-13
BRPI9607851B8 (pt) 2019-11-05
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
EP0817637A1 (en) 1998-01-14
CN1103593C (zh) 2003-03-26
EA000626B1 (ru) 1999-12-29
EP0817637B1 (en) 2002-07-17
CA2216634C (en) 2004-07-20
PL322532A1 (en) 1998-02-02
EA000626B3 (ru) 2016-04-29
NO974510L (no) 1997-09-29
FR05C0022I2 (enExample) 2005-10-21
DE122005000029I2 (de) 2006-04-27
NL300195I2 (nl) 2005-11-01
UA60293C2 (uk) 2003-10-15
NO974510D0 (no) 1997-09-29
OA10616A (en) 2001-03-15
HUP9801571A2 (hu) 1999-01-28
CZ295940B6 (cs) 2005-12-14
DE122005000029I1 (de) 2005-10-06
ES2179193T3 (es) 2003-01-16
BR9607851B1 (pt) 2009-01-13
SI0817637T1 (en) 2002-10-31
FR05C0022I1 (enExample) 2005-06-10
CA2216634A1 (en) 1996-10-03
NO2005014I1 (no) 2005-06-06
BR9607851A (pt) 1998-07-21
SK129597A3 (en) 1998-07-08
JPH10511682A (ja) 1998-11-10
HUP9801571A3 (en) 2001-04-28
EE04047B1 (et) 2003-06-16
RO117995B1 (ro) 2002-12-30
EE9700240A (et) 1998-04-15

Similar Documents

Publication Publication Date Title
BRPI9612992B1 (pt) Combinação, e, formulação farmacêutica
ES2213217T3 (es) Combinaciones que comprenden vx478, zidovudina, y 3tc para uso en el tratamiento de infecciones por vih.
US6486136B1 (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
US20020002180A1 (en) Antiviral combinations
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of
HK1009401B (en) Synergistic combinations

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/1996, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/03/2016.